Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ARGX
ARGX logo

ARGX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy argenx SE (ARGX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
877.720
1 Day change
-1.63%
52 Week Range
934.620
Analysis Updated At
2026/06/18
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Based on the data provided, Argenx SE (ARGX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support with significant upside potential, a bullish technical setup, and positive catalysts such as upcoming Phase 3 data for Vyvgart and ALKIVIA studies. While there are no immediate trading signals or recent news, the overall sentiment and growth prospects make it a compelling long-term investment.

Technical Analysis

The technical indicators suggest a bullish trend. The MACD is above 0 and positively contracting, RSI is neutral at 52.622, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level (880.751), with key resistance at 905.963 and support at 855.539.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The options data indicates a slightly bearish sentiment in the short term, with higher put volume compared to call volume. However, implied volatility is low, suggesting limited market uncertainty.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
7

Positive Catalysts

  • Strong analyst ratings with multiple price target increases, including Wells Fargo's target of $1,291, indicating significant upside potential.

  • Upcoming Phase 3 data for Vyvgart and ALKIVIA studies in Q3 2026, which could act as a major catalyst.

  • Durable growth in Vyvgart's revenue, with projections exceeding $6B in FY26.

Neutral/Negative Catalysts

  • Slightly bearish sentiment in options trading with a higher put-call volume ratio.

  • No recent news or significant insider or hedge fund activity to provide additional momentum.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are overwhelmingly positive on the stock, with multiple buy and overweight ratings. Recent price target increases range from $1,016 to $1,291, reflecting confidence in the company's growth trajectory and upcoming catalysts.

Wall Street analysts forecast ARGX stock price to rise
17 Analyst Rating
Wall Street analysts forecast ARGX stock price to rise
14 Buy
3 Hold
0 Sell
Strong Buy
Current: 892.260
sliders
Low
858
Averages
1048
High
1317
Current: 892.260
sliders
Low
858
Averages
1048
High
1317
Wells Fargo
NULL
to
Overweight
maintain
AI Analysis
2026-06-01
Reason
Wells Fargo
Price Target
AI Analysis
2026-06-01
maintain
NULL
to
Overweight
Reason
Wells Fargo raised the firm's price target on Argenx to $1,291 from $1,260 and keeps an Overweight rating on the shares. The firm remains constructive into Vyvgart's Phase 3 myositis read out and believes the current setup offers attractive risk/reward, with incremental analysis supporting its view that positive data could reinforce Argenx's path to becoming a large-cap biotech.
Stifel
Alex Thompson
Buy
maintain
2026-05-29
Reason
Stifel
Alex Thompson
Price Target
2026-05-29
maintain
Buy
Reason
Stifel analyst Alex Thompson raised the firm's price target on Argenx to $1,255 from $1,222 and keeps a Buy rating on the shares. Phase 3 data for the ALKIVIA study of efgartigimod in Myositis due in Q3 is "the most important catalyst for ARGX in 2026," the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ARGX
Unlock Now

People Also Watch